The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationCore Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Oettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution Experience
Winter, J. M., Cameron, J. L., Campbell, K. A., Arnold, M. A., Chang, D. C., Coleman, J., Hodgin, M. B., Sauter, P. K., Hruban, R. H., Riall, T. S., et al. (2006) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2006.08.018 · Cited by 1,489
Variation in Hospital Mortality Associated with Inpatient Surgery
Ghaferi, A. A., Birkmeyer, J. D., & Dimick, J. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0903048 · Cited by 1,465
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
Pancreatic Cancer: Adjuvant Combined Radiation and Chemotherapy Following Curative Resection
Kaiser, M. H. (1985) · Archives of Surgery · doi:10.1001/archsurg.1985.01390320023003 · Cited by 1,406
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109
Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
Hwang, R. F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., Ji, B., Evans, D. B., & Logsdon, C. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5714 · Cited by 1,099
Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081
Self-citationMuller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902903 · Cited by 1,019
A paracrine requirement for hedgehog signalling in cancer
Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., Marshall, D., Fu, L., Januario, T., Kallop, D., et al. (2008) · Nature · doi:10.1038/nature07275 · Cited by 961
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Loehrer, P. J., Feng, Y., Cardenes, H., Wagner, L., Brell, J. M., Cella, D., Flynn, P., Ramanathan, R. K., Crane, C. H., Alberts, S. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8904 · Cited by 830
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 823
Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 786
Evans, D. B., Varadhachary, G. R., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Wang, H., Cleary, K. R., Staerkel, G. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8634 · Cited by 731
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouché, O., Bosset, J. F., Aparicio, T., Mineur, L., Azzedine, A., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn281 · Cited by 696
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 690
Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.-L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 650
Most Pancreatic Cancer Resections are R1 Resections
Esposito, I., Kleeff, J., Bergmann, F., Reiser, C., Herpel, E., Friess, H., Schirmacher, P., & Büchler, M. W. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9839-8 · Cited by 645
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 632
Ueno, H., Ioka, T., Ikeda, M., Ohkawa, S., Yanagimoto, H., Boku, N., Fukutomi, A., Sugimori, K., Baba, H., Yamao, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3680 · Cited by 628
Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., & Miller, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.082 · Cited by 588
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Maus, M. V., Haas, A. R., Beatty, G. L., Albelda, S. M., Levine, B. L., Liu, X., Zhao, Y., Kalos, M., & June, C. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0006 · Cited by 586
Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., & Buckels, J. A. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600446 · Cited by 557
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Lutz, E. R., Wu, A. A., Bigelow, E., Sharma, R., Mo, G., Soares, K., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 550
Katz, M. H. G., Fleming, J. B., Bhosale, P., Varadhachary, G., Lee, J. E., Wolff, R., Wang, H., Abbruzzese, J., Pisters, P. W. T., Vauthey, J., et al. (2012) · Cancer · doi:10.1002/cncr.27636 · Cited by 536
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411679111 · Cited by 502
Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4869 · Cited by 501
Oettle, H., Riess, H., Stieler, J. M., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 487
Janus kinases: components of multiple signaling pathways
Rane, S. G., & Reddy, E. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203925 · Cited by 466
Varadhachary, G. R., Wolff, R. A., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Abdalla, E., Wang, H., Staerkel, G. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8642 · Cited by 466
Pancreatic Adenocarcinoma, Version 2.2014
Tempero, M. A., Malafa, M. P., Behrman, S. W., Benson, A. B., Casper, E. S., Chiorean, E. G., Chung, V., Cohen, S. J., Czito, B., Engebretson, A., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0106 · Cited by 465
Beatty, G. L., Torigian, D. A., Chiorean, E. G., Saboury, B., Brothers, A., Alavi, A., Troxel, A. B., Sun, W., Teitelbaum, U. R., Vonderheide, R. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1320 · Cited by 456
Mellor, A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K., Hansen, A., Koni, P. A., Iwashima, M., & Munn, D. H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1652 · Cited by 455
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
Sultana, A., Smith, C. T., Cunningham, D., Starling, N., Neoptolemos, J. P., & Ghaneh, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2551 · Cited by 442
Ellis, L. M., Bernstein, D. S., Voest, E. E., Berlin, J. D., Sargent, D., Cortazar, P., Garrett-Mayer, E., Herbst, R. S., Lilenbaum, R. C., Sima, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8009 · Cited by 442
Poplin, E., Feng, Y., Berlin, J., Rothenberg, M. L., Hochster, H., Mitchell, E., Alberts, S., O'Dwyer, P., Haller, D., Catalano, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9007 · Cited by 438
Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma
Rasheed, Z. A., Yang, J., Wang, Q., Kowalski, J., Freed, I., Murter, C., Hong, S.-M., Koorstra, J.-B., Rajeshkumar, N. V., He, X., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp535 · Cited by 437
Self-citationHeinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Erkan, M., Michalski, C. W., Rieder, S., Reiser–Erkan, C., Abiatari, I., Kolb, A., Giese, N. A., Esposito, I., Friess, H., & Kleeff, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.05.006 · Cited by 424
Frese, K. K., Neesse, A., Cook, N., Bapiro, T. E., Lolkema, M. P., Jodrell, D. I., & Tuveson, D. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0242 · Cited by 415
STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis
Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., & Bardeesy, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0908 · Cited by 413
Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Létourneau, R., Okusaka, T., Funakoshi, A., Furuse, J., Park, Y. S., Ohkawa, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70004-3 · Cited by 403
Richter, A., Niedergethmann, M., Sturm, J. W., Lorenz, D., Post, S., & Trede, M. (2003) · World Journal of Surgery · doi:10.1007/s00268-002-6659-z · Cited by 401
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
Ercolini, A. M., Ladle, B. H., Manning, E. A., Pfannenstiel, L. W., Armstrong, T. D., Machiels, J.-P. H., Bieler, J. G., Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042167 · Cited by 399
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L.-A., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 392
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Navas, C., Hernández-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., & Barbacid, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.001 · Cited by 391
Ohuchida, K., Mizumoto, K., Murakami, M., Qian, L.-W., Sato, N., Nagai, E., Matsumoto, K., Nakamura, T., & Tanaka, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2464 · Cited by 384
Wacker, B., Nagrani, T., Weinberg, J., Witt, K., Clark, G., & Cagnoni, P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2610 · Cited by 384
Drummond, D. C., Noble, C. O., Guo, Z., Hong, K., Park, J. W., & Kirpotin, D. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4007 · Cited by 380
Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70236-0 · Cited by 378
Herman, J. M., Swartz, M. J., Hsu, C. C., Winter, J., Pawlik, T. M., Sugar, E., Robinson, R., Laheru, D. A., Jaffee, E., Hruban, R. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8469 · Cited by 375
Self-citationWolpin, B. M., Rubinson, D. A., Wang, X., Chan, J. A., Cleary, J. M., Enzinger, P. C., Fuchs, C. S., McCleary, N. J., Meyerhardt, J. A., Ng, K., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0086 · Cited by 374
Infante, J. R., Somer, B. G., Park, J. O., Li, C.-P., Scheulen, M. E., Kasubhai, S. M., Oh, D.-Y., Liu, Y., Redhu, S., Steplewski, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.024 · Cited by 370
Le, D. T., Brockstedt, D. G., Nir-Paz, R., Hampl, J., Mathur, S., Nemunaitis, J., Sterman, D. H., Hassan, R., Lutz, E., Moyer, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2121 · Cited by 369
Improvement of surgical results for pancreatic cancer
Hartwig, W., Werner, J., Jäger, D., Debus, J., & Büchler, M. W. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70172-4 · Cited by 368
Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
De Bacco, F., Luraghi, P., Medico, E., Reato, G., Girolami, F., Perera, T., Gabriele, P., Comoglio, P. M., & Boccaccio, C. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr093 · Cited by 363
Mukherjee, S., Hurt, C. N., Bridgewater, J., Falk, S., Cummins, S., Wasan, H., Crosby, T., Jephcott, C., Roy, R., Radhakrishna, G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70021-4 · Cited by 355
Laheru, D., Lutz, E., Burke, J., Biedrzycki, B., Solt, S., Onners, B., Tartakovsky, I., Nemunaitis, J., Le, D., Sugar, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0371 · Cited by 346
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., Garner, E., Campbell, F., Mackey, J. R., Costello, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt347 · Cited by 337
Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325
Butturini, G. (2008) · Archives of Surgery · doi:10.1001/archsurg.2007.17 · Cited by 309
Oettle, H., Richards, D., Ramanathan, R. K., van Laethem, J. L., Peeters, M., Fuchs, M., Zimmermann, A., John, W., Von Hoff, D., Arning, M., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi309 · Cited by 306
Immunohistochemical Labeling for Dpc4 Mirrors Genetic Status in Pancreatic Adenocarcinomas
Wilentz, R. E., Su, G. H., Dai, J. L., Sparks, A. B., Argani, P., Sohn, T. A., Yeo, C. J., Kern, S. E., & Hruban, R. H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64703-7 · Cited by 304
Colucci, G., Labianca, R., Di Costanzo, F., Gebbia, V., Cartenì, G., Massidda, B., Dapretto, E., Manzione, L., Piazza, E., Sannicolò, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4433 · Cited by 304
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Goggins, M. G., Hruban, R. H., Cote, M. L., McWilliams, R. R., Roberts, N. J., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.153 · Cited by 295
Mutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
Alvarez, R., Musteanu, M., Garcia-Garcia, E., Lopez-Casas, P. P., Megias, D., Guerra, C., Muñoz, M., Quijano, Y., Cubillo, A., Rodriguez-Pascual, J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.415 · Cited by 293
Self-citationMolecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Quintás-Cardama, A., & Verstovsek, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0284 · Cited by 284
Abou-Alfa, G. K., Letourneau, R., Harker, G., Modiano, M., Hurwitz, H., Tchekmedyian, N. S., Feit, K., Ackerman, J., De Jager, R. L., Eckhardt, S. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0201 · Cited by 282
Faris, J. E., Blaszkowsky, L. S., McDermott, S., Guimaraes, A. R., Szymonifka, J., Huynh, M. A., Ferrone, C. R., Wargo, J. A., Allen, J. N., Dias, L. E., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0435 · Cited by 278
Jimeno, A., Feldmann, G., Suárez-Gauthier, A., Rasheed, Z., Solomon, A., Zou, G.-M., Rubio-Viqueira, B., García-García, E., López-Ríos, F., Matsui, W., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0924 · Cited by 276
Self-citationIjichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42754 · Cited by 256
Villarroel, M. C., Rajeshkumar, N. V., Garrido-Laguna, I., De Jesus-Acosta, A., Jones, S., Maitra, A., Hruban, R. H., Eshleman, J. R., Klein, A., Laheru, D., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0893 · Cited by 249
Self-citationGarrido-Laguna, I., Uson, M., Rajeshkumar, N. V., Tan, A. C., de Oliveira, E., Karikari, C., Villaroel, M. C., Salomon, A., Taylor, G., Sharma, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0341 · Cited by 247
Self-citationGonçalves, A., Gilabert, M., François, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R., Gasmi, M., Tchiknavorian, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds135 · Cited by 225
The immune network in pancreatic cancer development and progression
Wörmann, S. M., Diakopoulos, K. N., Lesina, M., & Algül, H. (2014) · Oncogene · doi:10.1038/onc.2013.257 · Cited by 205
for the European Study Group of Pancreatic Cancer, Neoptolemos, J. P., Stocken, D. D., Tudur Smith, C., Bassi, C., Ghaneh, P., Owen, E., Moore, M., Padbury, R., Doi, R., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604838 · Cited by 204
Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials
Assifi, M. M., Lu, X., Eibl, G., Reber, H. A., Li, G., & Hines, O. J. (2011) · Surgery · doi:10.1016/j.surg.2011.07.006 · Cited by 193
Bidard, F. C., Huguet, F., Louvet, C., Mineur, L., Bouché, O., Chibaudel, B., Artru, P., Desseigne, F., Bachet, J. B., Mathiot, C., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt176 · Cited by 192
Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1980 · Cited by 190
Harder, J., Ihorst, G., Heinemann, V, Hofheinz, R., Moehler, M., Buechler, P., Kloeppel, G., Röcken, C., Bitzer, M., Boeck, S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.18 · Cited by 188
Andriulli, A., Festa, V., Botteri, E., Valvano, M. R., Koch, M., Bassi, C., Maisonneuve, P., & Sebastiano, P. D. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2110-8 · Cited by 187
Rougier, P., Riess, H., Manges, R., Karasek, P., Humblet, Y., Barone, C., Santoro, A., Assadourian, S., Hatteville, L., & Philip, P. A. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.002 · Cited by 184
Yoo, C., Hwang, J. Y., Kim, J.-E., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. S., Seo, D. W., Lee, S. K., Kim, M.-H., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 170
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Melero, I., Grimaldi, A. M., Perez-Gracia, J. L., & Ascierto, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2214 · Cited by 170
Abrams, J., Conley, B., Mooney, M., Zwiebel, J., Chen, A., Welch, J. J., Takebe, N., Malik, S., McShane, L., Korn, E., et al. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.71 · Cited by 159
da Cunha Santos, G., Dhani, N., Tu, D., Chin, K., Ludkovski, O., Kamel‐Reid, S., Squire, J., Parulekar, W., Moore, M. J., & Tsao, M. S. (2010) · Cancer · doi:10.1002/cncr.25393 · Cited by 158
Witkiewicz, A., Williams, T. K., Cozzitorto, J. A., Durkan, B., Showalter, S. L., Yeo, C. J., & Brody, J. R. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.12.014 · Cited by 158
Chini, C. C. S., Guerrico, A. M. G., Nin, V., Camacho-Pereira, J., Escande, C., Barbosa, M. T., & Chini, E. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0150 · Cited by 149
Kim, S. T., Lim, D. H., Jang, K.-T., Lim, T., Lee, J., Choi, Y.-L., Jang, H.-L., Yi, J. H., Baek, K. K., Park, S. H., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0269 · Cited by 145
Gunturu, K. S., Yao, X., Cong, X., Thumar, J. R., Höchster, H. S., Stein, S., & Lacy, J. (2012) · Medical Oncology · doi:10.1007/s12032-012-0361-2 · Cited by 140
Clinical and molecular characterization of HER2amplified-pancreatic cancer
Chou, A. S. Y., Waddell, N., Cowley, M. J., Gill, A. J., Chang, D. K.-F., Patch, A., Nones, K., Wu, J., Pinese, M., Johns, A. L., et al. (2013) · Genome Medicine · doi:10.1186/gm482 · Cited by 136
Johnson, D. B., Dahlman, K. H., Knol, J., Gilbert, J., Puzanov, I. J., Means-Powell, J. A., Balko, J. M., Lovly, C. M., Murphy, B. A., Goff, L. W., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0011 · Cited by 116
Laheru, D. A., Shah, P., Rajeshkumar, N. V., McAllister, F. M., Taylor, G., Goldsweig, H. G., Le, D. T., Donehower, R. C., Jimeno, A., Linden, S., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9818-6 · Cited by 104
Self-citationRajeshkumar, N. V., Rasheed, Z. A., García-García, E., López‐Ríos, F., Fujiwara, K., Matsui, W. H., & Hidalgo, M. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0370 · Cited by 99
Self-citationZaniboni, A., Aitini, E., Barni, S., Ferrari, D., Cascinu, S., Catalano, V., Valmadre, G., Ferrara, D., Veltri, E. M., Codignola, C., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1875-1 · Cited by 90
mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome
Klümpen, H., Queiroz, K. C. S., Spek, C. A., van Noesel, C. J. M., Brink, H. C., de Leng, W. W. J., de Wilde, R. F., Mathus-Vliegen, E. M. H., Offerhaus, G. J. A., Alleman, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7825 · Cited by 89
Hammel, P. R., Huguet, F., Laethem, J. V., Goldstein, D., Glimelius, B. L. G., Artru, P., Borbath, I., Bouché, O., Shannon, J., André, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.lba4003 · Cited by 86
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
Garrido‐Laguna, I., Tan, A. C., Uson, M. L., Angenendt, M., W, W., Villaroel, M. C., Zhao, M., Rajeshkumar, N. V., Jimeno, A., Donehower, R. C., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605819 · Cited by 80
Self-citationUS National Cancer Institute's new Ras project targets an old foe
Thompson, H. (2013) · Nature Medicine · doi:10.1038/nm0813-949 · Cited by 74
Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply
Le, A., Rajeshkumar, N. V., Maitra, A., & Dang, C. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0041 · Cited by 61
Jesus‐Acosta, A. D., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Maitra, A., Rasheed, Z. A., Zheng, L., Rajeshkumar, N. V., Le, D. T., Hoering, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.257 · Cited by 53
Mining the genomes of exceptional responders
Chang, D. K.-F., Grimmond, S. M., Evans, T. R. J., & Biankin, A. V. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3723 · Cited by 41
Catenacci, D. V. T., Bahary, N., Nattam, S. R., Marsh, R., Wallace, J. A., Rajdev, L. N., Cohen, D. J., Sleckman, B. G., Lenz, H., Stiff, P. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4012 · Cited by 39
Ormanns, S., Siveke, J. T., Heinemann, V., Haas, M., Sipos, B., Schlitter, A. M., Esposito, I., Jung, A., Laubender, R. P., Krüger, S., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-624 · Cited by 34
O'Reilly, E. M., Lowery, M. A., Segal, M. F., Smith, S., Moore, M. J., Kindler, H. L., Golan, T., Segal, A., Salo‐Mullen, E. E., Hollywood, E. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.4023 · Cited by 34
Evidence for the Importance of Personalized Molecular Profiling in Pancreatic Cancer
Lili, L. N., Matyunina, L. V., Walker, L. D., Daneker, G. W., & McDonald, J. F. (2014) · Pancreas · doi:10.1097/mpa.0000000000000020 · Cited by 33
Cutsem, E. V., Hidalgo, M. M., Bazin, I. S., Canon, J.-L. R., Poddubskaya, E. V., Manojlovic, N. S., Milella, M., Radenkovic, D. V., Verslype, C., Guo, W. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.344 · Cited by 22
Self-citationJAK V617F missense mutation is absent in pancreatic cancer: Table 1
Kocher, H. M., Mears, L., Lea, N. C., Raj, K. K., & Mufti, G. (2007) · Gut · doi:10.1136/gut.2006.117754 · Cited by 12
Ryan, D. P., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D. S., Cohn, A. L., Schelman, W. R., Stephenson, J., Eng, C., & Borad, M. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.4_suppl.325 · Cited by 7
Cited by
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
McGuigan, A., Kelly, P., Turkington, R. C., Jones, C., Coleman, H. G., & McCain, R. S. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i43.4846 · Cited by 1,908
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.008 · Cited by 1,577
“This represents a significant unmet need, as most chemotherapeutic and immunotherapeutic agents that have proven efficacy in other malignancies have limited efficacy in PDAC (Garrido-Laguna and Hidalgo, 2015; Manji et al., 2017).”
BackgroundModulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Microenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Metadata
- Authors
- Garrido-Laguna, I., & Hidalgo, M.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2015-03-31
- Volume
- 12
- Issue
- 6
- Pages
- 319-334
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2164942973
- Cited by
- 565
- References
- 155
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.